Our previous studies indicated that elevated expression of erbB3 led to paclitaxel resistance in erbB2-overexpressing breast cancer cells via PI-3 K/Akt signaling-dependent upregulation of Survivin [27]. Here, ERBB3 is linked to breast carcinoma.